Survivin在食管癌肿瘤组织中高表达机制的研究
|
摘要
食管癌是人类九种最常见的恶性肿瘤之一,全世界每年新增病例30万,其中70 %的病例发生在我国,并且其发病率仍呈上升趋势。食管癌是高致死性的疾病,术后5年生存率仅20 % ~ 30 %。因此,研究食管癌的发病机制,寻找新的诊断和治疗靶点,已经成为提高其预防和治疗效果的当务之急。
肿瘤是一个多基因参与的与细胞周期紊乱和凋亡受阻密切相关的疾病。Survivin是凋亡抑制蛋白(IAP)家族的成员之一,不仅抑制凋亡,也参与细胞有丝分裂,在细胞凋亡和细胞周期的基因调控中发挥重要作用。正常情况下,survivin表达于胚胎和发育的胎儿组织细胞,不表达于终末分化的组织细胞。而在大多数人类肿瘤中,survivin在肿瘤细胞重新获得高表达,但在相应的癌旁组织中无表达。已有大量的研究证实,肿瘤细胞高表达survivin在肿瘤发生、发展过程中起着重要的作用,其表达水平同多种肿瘤的恶性程度、对放、化疗的抵抗性、以及肿瘤的不良预后呈正相关。因此,survivin已被用作新的肿瘤标志物,成为肿瘤诊断和治疗的研究热点。由于survivin在肿瘤组织中异常高表达的独特方式,探讨其表达调控机制,以用于肿瘤的治疗就成为人们关注的一个重要问题。
研究表明,肿瘤组织中survivin的表达调控主要发生在转录水平。已有研究报道了多种转录因子,包括:Sp1、Sp3、Egr-1、Stat3和Rb/E2F、p53等参与不同细胞survivin mRNA的转录调控,survivin在肿瘤组织中的高表达有可能由这些转录因子的异常所引起。在参与到survivin转录调控的转录因子中,野生型p53对survivin表达的负调节作用近年来很受关注。Survivin启动子区含有p53转录因子的结合位点,野生型p53可直接结合survivin启动子进而抑制survivin启动子的活性,p53突变之后则失去了野生型p53的功能。在以往的研究中,尚未有涉及食管癌肿瘤组织中survivin表达与p53突变关系的报道,因此,进一步探讨食管癌组织survivin表达是否受野生型p53调节,对明确食管癌中survivin高表达的调节机制具有重要的价值。
单核苷酸多态(single nucleotide polymorphism,SNP)被认为是一种稳定遗传的早期突变,与疾病有着稳定的相关性。研究表明在survivin的启动子和编码区域均发现有SNPs变异,这些SNPs位点可能与survivin的表达调控相关,从而与机体对食管癌的易感性相关联。在本研究中,我们利用公布的SNP数据(http://pga.gs.washington.edu、http://www.ncbi.nlm.nih.gov)结合文献检索与生物信息学分析选取了survivin基因启动子区五个多态性位点(-31G/C、-141G/C、-241T/C、-625G/C、-644T/C),首先了解这些多态位点在重庆地区正常人群中的频率分布,比较与其他公布的人种数据的差异。在此基础上,利用我们已经建立的食管癌临床资料和DNA样本数据库,采用病例对照的设计方法,进一步检测上述多态位点在食管癌人群中的基因型和等位基因频率,并从单位点分析、单倍型分析等方面,探讨survivin启动子多态性与食管癌患病风险之间的关联,分析survivin启动子区的多态位点与食管癌组织中survivin表达的相关性,筛查与食管癌survivin基因高表达相关联的SNP位点,为进一步研究分析其影响表达调控的分子机制奠定基础。
DNA甲基化修饰是表观遗传修饰的主要方式,甲基化主要发生于基因启动子附近的CpG富集区域(又称CpG岛)。迄今为止,关于肿瘤癌基因异常激活和抑癌基因失活与该基因的启动子区域CpG岛甲基化的直接关系已有大量的报道。Survivn基因含有一个大的CpG岛,从启动子区一直延伸到第一外显子区域,提示其甲基化修饰可参与survivin基因的转录调控。本研究首先选择少量survivin mRNA表达状态有差异的食管癌及匹配的癌旁组织标本,检测survivin基因第一外显子区甲基化状态差异,以期对阐明食管癌组织survivin启动子甲基化状态是否参与其表达调节提供初步线索。
综上所述,为了揭示survivin在食管癌肿瘤组织中异常表达的可能机制,综合目前针对survivin表达调控以及肿瘤组织中survivin异常表达机制的研究现状,本研究检测了食管癌中可能影响survivin表达的转录因子(p53突变),以及遗传学(启动子多态性)、表观遗传学(CpG岛甲基化)机制,通过初步研究,获得了以下结果:
1.分析survivin mRNA表达与p53基因突变之间的关系。收集100例食管癌组织标本,利用RT-PCR检测了survivin mRNA的表达,总表达率为64 %;PCR-SSCP法检测了肿瘤组织中p53基因第5、6、7、8号外显子突变,总突变率为31 %。突变型p53组survivin mRNA阳性率为80.6 %,野生型p53组survivin mRNA阳性率只有56.5 %,两组survivin mRNA阳性率存在显著差异(p=0.020),突变型p53组survivin mRNA阳性率显著高于野生型p53组。
2.选择survivin基因启动子区五个多态位点(-31G/C、-141G/C、-241T/C、-625G/C和-644T/C),利用PCR-RFLP或PCR-错配引物酶切的方法对重庆地区正常汉族人群进行基因分型。将所得数据与NCBI SNP数据库数据作比较,结果显示,-31G/C、-241T/C、-644T/C位点在重庆汉族人中的分布与NCBI中全球数据有显著差异。重庆汉族人-31G/C、-644T/C位点数据与NCBI亚洲人群的数据基本一致,与欧洲人和非洲人的数据分布相比差异显著。重庆汉族人-625G/C位点数据与亚洲人、非洲人群数据分布有显著差异。提示survivin启动子的多态性在不同种族间分布频率存在着差异。
3.采用病例-对照的设计方法,分析了survivin启动子多态性及单倍型与食管癌患病风险之间的关系。结果显示:(1)-31G/C和-644T/C位点的等位基因型和基因型在对照组及肿瘤组之间的分布没有显著差异。而-625G/C位点与食管癌发病风险相关。Survivin启动子-625G/C多态位点的CC纯合基因型食管癌发病风险是另两种基因型的2.120倍(95%CI:1.247-3.603)。(2)以-31G/C、-625G/C和-644T/C三个位点为核心构建单倍型,单体型-644T--625C--31C在食管癌病人组中出现的概率是在对照组中出现概率的2.473倍(95%CI,1.532~3.994),拥有此单体型的病人患食管癌的风险较高。-644T--625G--31C为一个保护性的单体型(OR = 0.736),拥有此单体型的个体比较不容易患食管癌(95%CI,0.573~0.946)。单体型的分析结果与单个位点分析结果一致。
4.分析了survivin启动子多态性与食管癌肿瘤组织survivin表达之间的关系,结果发现:-31G/C和-644T/C位点的等位基因型、基因型在survivin阳性表达组和survivin阴性表达组之间的分布并没有显著差异。而-625G/C位点等位基因型以及基因型分布在两组之间均有显著性差异(p值分别为0.024、0.033),提示-625C等位基因与肿瘤组织survivin的高表达相关。
5.检测食管癌肿瘤组织中survivin基因甲基化状态。选取肿瘤组织有明显survivin表达而相应的癌旁组织检测不到survivin表达的4对肿瘤、癌旁组织标本作为研究对象,用亚硫酸盐修饰后测序的方法检测其survivin第一外显子的甲基化状态。初步结果显示, survivin阳性的肿瘤组织和survivin阴性的癌旁组织,其survivin基因第一外显子的甲基化状态相同,survivin第一外显子区所有的CpG位点都呈非甲基化状态。初步提示食管癌肿瘤组织中survivin的高表达可能并非由survivin基因甲基化失常而引起。由于本研究样本例数较少,阐明食管癌组织survivin启动子的甲基化状态是否参与其表达调节尚需更大样本的后续研究来进行。
本研究的结果揭示了食管癌肿瘤组织中survivin异常高表达的部分机制,为食管癌发病分子机制的研究提供了线索,进而为食管癌的诊断提供预防和预后信息,以及给食管癌的治疗提供新的途径。
Esophageal cancer is regarded as the ninth most common malignancy worldwide. Compared with other nations, there is higher incidence in China. Esophageal cancer is an extremely fatal disease. In spite of major advancement in cancer treatment, prognosis is still poor.
Owing to recent advancements in tumor biology, apoptosis plays an important role in organ homeostasis, impairment of apoptosis facilitates the accumulation of gene mutations by prolonging the cell cycle span and promoting resistance to immune-based cytotoxicity, finally contributing to carcinogenesis. Survivin is an inhibitor of apoptosis protein, which blocks apoptosis induced by a variety of triggers. Survivin plays an important role in the development and progression of cancers. The expression of survivin is ubiquitous in fetal tissues, but is negligible in the majority of terminally differentiated adult tissues. In various cancers including esophageal cancer, survivin is significantly overexpressed. However, mechanism of survivin being re-expressed in cancers is still unclear and remains to be further studied.
Many researches using RT-PCR showed a high level of survivin mRNA in cancer tissues compared with normal tissues, indicating that the survivin overexpression in cancers may arise predominately at the level of transcriptional regulation of the survivin gene. There are many transcription factors regulated survivin transcription in various cell types, including Sp1, Sp3, Egr-1, Stat3Rb, E2F and p53. Among these transcription factors, p53 is especially important in tumors. Like survivin, p53 is also a critical mediator of apoptosis and tumorigenesis. The p53 gene is mutated in various human cancers. In vitro transient transfection demonstrated that the expression of wild type p53 was associated with strong repression of the survivin promoter activity in various cell types, while mutant p53 wasn’t. Several clinical studies revealed that the p53 gene mutation might contribute to aberrant survivin expression in non-small cell lung cancers, breast cancers and laryngeal squamous cell carcinomas. While other clinical studies displayed different results. Kawasaki et al indicated that the survivin expression in colon cancer tissues had no relation with p53 mutation; Tanaka et al drawed the same conclusion in breast cancers. Whether the p53 gene mutation contributes to aberrant survivin expression in esophageal cancers or not is yet to be determined. In order to study the possible correlation between p53 and survivin in esophageal cancers, we compared survivin expression between the cancer tissues of wild type p53 and that of mutant p53.
Single-nucleotide polymorphisms (SNP) are inheritable mutation and had steady correlation with various diseases. Several polymorphisms in survivin promoter have been identified previously. These SNPs might be correlated with the risk of tumors. The SNPs data of survivin gene in the NCBI (National Center for Biotechnology Information) SNP database are mainly submitted by European, American or Japanese, and the majority of SNPs have no information about the frequency distribution in different race. The SNP frequencies in various race are different, the SNPs’distribution in survivin gene region in Chinese Han nationality and the function of these SNPs have not been satisfactorily described yet. After searched the public SNP database (http://pga.gs.washington.edu, http://www.ncbi.nlm.nih.gov) and literatures, we identified five SNPs, -31G/C, -141G/C, -241T/C, -644T/C and -625G/C. In the present study, we compared these SNPs’distribution in Chinese Han nationality of Chongqing city with the frequency distribution in other race of people. Then we analyzed the relationship between the survivin promoter polymorphisms and the survivin expression of corresponding tumor tissues in order to detect whether the SNPs influence survivin expression or not. Moreover, we have compared the frequency of four survivin promoter polymorphisms in Chinese sporadic esophageal cancer patients and healthy controls in an attempt to identify a possible association between individual genetic variation and susceptibility to esophageal cancer.
CpG methylation is thought to be critical for regulating transcription by the GC rich region around the transcription start site. Survivin has a large CpG island spanning from promoter to exon1 region, which increases the possibility that survivin overexpression in cancers may be the result of the dys-methylation status in neoplastic cells. However, Li and Altieri demonstrated that the CpG island in the survivin promoter was unmethylated in both normal and neoplastic tissues in breast, lung and colon cancers. In contrast, there were other researches reporting that demethylation of CpG sites in the survivin gene exon 1 was involved in the survivin expression in ovarian and oral cancers. These different data indicated that the methylation status of the human survivin promoter might depend on the different CpG sites reserchers detected. We are interested in the methylation status of survivin exon 1 region in esophageal cancer, so whether the CpG island in survivin gene is methylated in normal cells and unmethylated in esophageal cancer were studied in this research.
In summary, our study is to investigate the mechanisms of survivin overexpression in esophageal cancer, the following data showed the contents and results of our study:
1. Esophageal cancer with mutant p53 showed higher survivin gene expression. We measured survivin mRNA expression using RT-PCR in esophageal cancer and adjacent non-cancerous tissues of 100 patients. PCR-single-strand conformation polymorphism (SSCP) analysis was used to detect exons 5–8 mutations of the p53 gene in espohageal cancer tissues. To determine whether the loss of wild type p53 enhanced survivin gene expression in esophageal cancer tissue, the relationship between survivin mRNA expression and p53 gene mutation was analyzed. The ratio of survivin-positive tumors was significantly higher in tumors with mutant p53 than that in tumors with wild type p53 (P=0.020).
2. Polymorphisms of survivin promoter were identified using the PCR-RFLP technique (-31G/C, -141G/C, -241T/C) or primer-introduced restriction analysis-PCR assay (-644T/C, -625G/C). We compared these SNPs’distribution in Chinese Han nationality of Chongqing city with the data in NCBI database about the frequency distribution in other race of people. We found significant differences in allele frequencies of -31G/C, -241T/C and -644T/C polymorphisms between Chinese Han nationality of Chongqing city and the NCBI data of global people. The allele frequencies of -31G/C and -644T/C polymorphisms in Chinese Han nationality of Chongqing city were equal to the NCBI’Asia data, but were different to the European and African data. There was significant difference in allele frequencies of -625G/C polymorphisms between Chinese Han nationality of Chongqing city and the NCBI data of Asia and African people.
3. Polymorphisms of Survivin Promoter Are Associated with Risk of Esophageal Cancer. The frequencies of -644T/C and -31G/C polymorphisms were not significantly different between patients and controls. However, the significant differences in both allele and genotype frequencies between esophageal cancer patients and cancer-free controls were found in -625G/C polymorphism. Compared with the other genotype, the -625CC genotype was associated with significant elevated risk of esophageal cancer (OR=2.120, 95%CI: 1.247-3.603).
4. We examined the combined effect of the survivin promoter polymorphisms, the haplotypes constructed of -644T/C, -625G/C, -31G/C revealed significant associations with esophageal cancer (global P = 0.0034). -644T--625C--31C was a risk haplotype for esophageal cancer (P=0.0001) and -644T?-625G?-31C, a protective haplotype (P = 0.0165).
5. Survivin expression was associated with survivin promoter polymorphisms. The difference between the groups of different survivin expression level was statistically significant to the -625G/C polymorphism (P = 0.024), but not obvious for the -31G/C and -644T/C polymorphisms. The variant C-allele in the -625G/C SNP site was associated with a higher possibility of survivin expression in esophageal cancer patients. Furthermore, the patients with survivin-negative cancer tissues were more likely to exhibit the GG genotype (p=0.033).
6. We investigated the methylation profiles of the survivin exon1 using BSP method in esophageal cancer and adjacent non-cancerous tissues of 4 patients. The cancer tissues we studied were survivin-positive and matched normal tissues were survivin-negative. After BSP, we didn’t find any cytosines in the PCR products’sequences. Therefore, the survivin exon 1 had no methylated CpG site. The survivin-negative non-cancerous tissues and the survivin-positive cancer tissues didn’t show different methylation status in the regions at least in the samples we studied.
Our results revealed an association between p53 mutation and increased survivin expression in esophageal cancer. At the same time, we found the survivin promoter -625CC genotype was more likely to have survivin expression in cancer tissue. These provided substantial mechanism contributing to survivin up-regulation in esophageal cancer. Furthermore, our case-control study suggests a significant association between survivin promoter SNP and esophageal cancer. Moreover, we identified the high consistency of a common risk (-644T?-625C?-31C) and a protective (-644T?-625G?-31C) haplotype in survivin promoter linked with esophageal cancer. To our knowledge, the present study is the first report demonstrating that survivin expression is negatively regulated by p53 gene status in esophageal cancer patients. This is also the first research showing a significant relationship between the survivin promoter -625G/C polymorphism with its mRNA expression and the risk of esophageal cancer. Although the association was statistically significant with the small number of samples, this needs to be confirmed with a larger sample.
肿瘤是一个多基因参与的与细胞周期紊乱和凋亡受阻密切相关的疾病。Survivin是凋亡抑制蛋白(IAP)家族的成员之一,不仅抑制凋亡,也参与细胞有丝分裂,在细胞凋亡和细胞周期的基因调控中发挥重要作用。正常情况下,survivin表达于胚胎和发育的胎儿组织细胞,不表达于终末分化的组织细胞。而在大多数人类肿瘤中,survivin在肿瘤细胞重新获得高表达,但在相应的癌旁组织中无表达。已有大量的研究证实,肿瘤细胞高表达survivin在肿瘤发生、发展过程中起着重要的作用,其表达水平同多种肿瘤的恶性程度、对放、化疗的抵抗性、以及肿瘤的不良预后呈正相关。因此,survivin已被用作新的肿瘤标志物,成为肿瘤诊断和治疗的研究热点。由于survivin在肿瘤组织中异常高表达的独特方式,探讨其表达调控机制,以用于肿瘤的治疗就成为人们关注的一个重要问题。
研究表明,肿瘤组织中survivin的表达调控主要发生在转录水平。已有研究报道了多种转录因子,包括:Sp1、Sp3、Egr-1、Stat3和Rb/E2F、p53等参与不同细胞survivin mRNA的转录调控,survivin在肿瘤组织中的高表达有可能由这些转录因子的异常所引起。在参与到survivin转录调控的转录因子中,野生型p53对survivin表达的负调节作用近年来很受关注。Survivin启动子区含有p53转录因子的结合位点,野生型p53可直接结合survivin启动子进而抑制survivin启动子的活性,p53突变之后则失去了野生型p53的功能。在以往的研究中,尚未有涉及食管癌肿瘤组织中survivin表达与p53突变关系的报道,因此,进一步探讨食管癌组织survivin表达是否受野生型p53调节,对明确食管癌中survivin高表达的调节机制具有重要的价值。
单核苷酸多态(single nucleotide polymorphism,SNP)被认为是一种稳定遗传的早期突变,与疾病有着稳定的相关性。研究表明在survivin的启动子和编码区域均发现有SNPs变异,这些SNPs位点可能与survivin的表达调控相关,从而与机体对食管癌的易感性相关联。在本研究中,我们利用公布的SNP数据(http://pga.gs.washington.edu、http://www.ncbi.nlm.nih.gov)结合文献检索与生物信息学分析选取了survivin基因启动子区五个多态性位点(-31G/C、-141G/C、-241T/C、-625G/C、-644T/C),首先了解这些多态位点在重庆地区正常人群中的频率分布,比较与其他公布的人种数据的差异。在此基础上,利用我们已经建立的食管癌临床资料和DNA样本数据库,采用病例对照的设计方法,进一步检测上述多态位点在食管癌人群中的基因型和等位基因频率,并从单位点分析、单倍型分析等方面,探讨survivin启动子多态性与食管癌患病风险之间的关联,分析survivin启动子区的多态位点与食管癌组织中survivin表达的相关性,筛查与食管癌survivin基因高表达相关联的SNP位点,为进一步研究分析其影响表达调控的分子机制奠定基础。
DNA甲基化修饰是表观遗传修饰的主要方式,甲基化主要发生于基因启动子附近的CpG富集区域(又称CpG岛)。迄今为止,关于肿瘤癌基因异常激活和抑癌基因失活与该基因的启动子区域CpG岛甲基化的直接关系已有大量的报道。Survivn基因含有一个大的CpG岛,从启动子区一直延伸到第一外显子区域,提示其甲基化修饰可参与survivin基因的转录调控。本研究首先选择少量survivin mRNA表达状态有差异的食管癌及匹配的癌旁组织标本,检测survivin基因第一外显子区甲基化状态差异,以期对阐明食管癌组织survivin启动子甲基化状态是否参与其表达调节提供初步线索。
综上所述,为了揭示survivin在食管癌肿瘤组织中异常表达的可能机制,综合目前针对survivin表达调控以及肿瘤组织中survivin异常表达机制的研究现状,本研究检测了食管癌中可能影响survivin表达的转录因子(p53突变),以及遗传学(启动子多态性)、表观遗传学(CpG岛甲基化)机制,通过初步研究,获得了以下结果:
1.分析survivin mRNA表达与p53基因突变之间的关系。收集100例食管癌组织标本,利用RT-PCR检测了survivin mRNA的表达,总表达率为64 %;PCR-SSCP法检测了肿瘤组织中p53基因第5、6、7、8号外显子突变,总突变率为31 %。突变型p53组survivin mRNA阳性率为80.6 %,野生型p53组survivin mRNA阳性率只有56.5 %,两组survivin mRNA阳性率存在显著差异(p=0.020),突变型p53组survivin mRNA阳性率显著高于野生型p53组。
2.选择survivin基因启动子区五个多态位点(-31G/C、-141G/C、-241T/C、-625G/C和-644T/C),利用PCR-RFLP或PCR-错配引物酶切的方法对重庆地区正常汉族人群进行基因分型。将所得数据与NCBI SNP数据库数据作比较,结果显示,-31G/C、-241T/C、-644T/C位点在重庆汉族人中的分布与NCBI中全球数据有显著差异。重庆汉族人-31G/C、-644T/C位点数据与NCBI亚洲人群的数据基本一致,与欧洲人和非洲人的数据分布相比差异显著。重庆汉族人-625G/C位点数据与亚洲人、非洲人群数据分布有显著差异。提示survivin启动子的多态性在不同种族间分布频率存在着差异。
3.采用病例-对照的设计方法,分析了survivin启动子多态性及单倍型与食管癌患病风险之间的关系。结果显示:(1)-31G/C和-644T/C位点的等位基因型和基因型在对照组及肿瘤组之间的分布没有显著差异。而-625G/C位点与食管癌发病风险相关。Survivin启动子-625G/C多态位点的CC纯合基因型食管癌发病风险是另两种基因型的2.120倍(95%CI:1.247-3.603)。(2)以-31G/C、-625G/C和-644T/C三个位点为核心构建单倍型,单体型-644T--625C--31C在食管癌病人组中出现的概率是在对照组中出现概率的2.473倍(95%CI,1.532~3.994),拥有此单体型的病人患食管癌的风险较高。-644T--625G--31C为一个保护性的单体型(OR = 0.736),拥有此单体型的个体比较不容易患食管癌(95%CI,0.573~0.946)。单体型的分析结果与单个位点分析结果一致。
4.分析了survivin启动子多态性与食管癌肿瘤组织survivin表达之间的关系,结果发现:-31G/C和-644T/C位点的等位基因型、基因型在survivin阳性表达组和survivin阴性表达组之间的分布并没有显著差异。而-625G/C位点等位基因型以及基因型分布在两组之间均有显著性差异(p值分别为0.024、0.033),提示-625C等位基因与肿瘤组织survivin的高表达相关。
5.检测食管癌肿瘤组织中survivin基因甲基化状态。选取肿瘤组织有明显survivin表达而相应的癌旁组织检测不到survivin表达的4对肿瘤、癌旁组织标本作为研究对象,用亚硫酸盐修饰后测序的方法检测其survivin第一外显子的甲基化状态。初步结果显示, survivin阳性的肿瘤组织和survivin阴性的癌旁组织,其survivin基因第一外显子的甲基化状态相同,survivin第一外显子区所有的CpG位点都呈非甲基化状态。初步提示食管癌肿瘤组织中survivin的高表达可能并非由survivin基因甲基化失常而引起。由于本研究样本例数较少,阐明食管癌组织survivin启动子的甲基化状态是否参与其表达调节尚需更大样本的后续研究来进行。
本研究的结果揭示了食管癌肿瘤组织中survivin异常高表达的部分机制,为食管癌发病分子机制的研究提供了线索,进而为食管癌的诊断提供预防和预后信息,以及给食管癌的治疗提供新的途径。
Esophageal cancer is regarded as the ninth most common malignancy worldwide. Compared with other nations, there is higher incidence in China. Esophageal cancer is an extremely fatal disease. In spite of major advancement in cancer treatment, prognosis is still poor.
Owing to recent advancements in tumor biology, apoptosis plays an important role in organ homeostasis, impairment of apoptosis facilitates the accumulation of gene mutations by prolonging the cell cycle span and promoting resistance to immune-based cytotoxicity, finally contributing to carcinogenesis. Survivin is an inhibitor of apoptosis protein, which blocks apoptosis induced by a variety of triggers. Survivin plays an important role in the development and progression of cancers. The expression of survivin is ubiquitous in fetal tissues, but is negligible in the majority of terminally differentiated adult tissues. In various cancers including esophageal cancer, survivin is significantly overexpressed. However, mechanism of survivin being re-expressed in cancers is still unclear and remains to be further studied.
Many researches using RT-PCR showed a high level of survivin mRNA in cancer tissues compared with normal tissues, indicating that the survivin overexpression in cancers may arise predominately at the level of transcriptional regulation of the survivin gene. There are many transcription factors regulated survivin transcription in various cell types, including Sp1, Sp3, Egr-1, Stat3Rb, E2F and p53. Among these transcription factors, p53 is especially important in tumors. Like survivin, p53 is also a critical mediator of apoptosis and tumorigenesis. The p53 gene is mutated in various human cancers. In vitro transient transfection demonstrated that the expression of wild type p53 was associated with strong repression of the survivin promoter activity in various cell types, while mutant p53 wasn’t. Several clinical studies revealed that the p53 gene mutation might contribute to aberrant survivin expression in non-small cell lung cancers, breast cancers and laryngeal squamous cell carcinomas. While other clinical studies displayed different results. Kawasaki et al indicated that the survivin expression in colon cancer tissues had no relation with p53 mutation; Tanaka et al drawed the same conclusion in breast cancers. Whether the p53 gene mutation contributes to aberrant survivin expression in esophageal cancers or not is yet to be determined. In order to study the possible correlation between p53 and survivin in esophageal cancers, we compared survivin expression between the cancer tissues of wild type p53 and that of mutant p53.
Single-nucleotide polymorphisms (SNP) are inheritable mutation and had steady correlation with various diseases. Several polymorphisms in survivin promoter have been identified previously. These SNPs might be correlated with the risk of tumors. The SNPs data of survivin gene in the NCBI (National Center for Biotechnology Information) SNP database are mainly submitted by European, American or Japanese, and the majority of SNPs have no information about the frequency distribution in different race. The SNP frequencies in various race are different, the SNPs’distribution in survivin gene region in Chinese Han nationality and the function of these SNPs have not been satisfactorily described yet. After searched the public SNP database (http://pga.gs.washington.edu, http://www.ncbi.nlm.nih.gov) and literatures, we identified five SNPs, -31G/C, -141G/C, -241T/C, -644T/C and -625G/C. In the present study, we compared these SNPs’distribution in Chinese Han nationality of Chongqing city with the frequency distribution in other race of people. Then we analyzed the relationship between the survivin promoter polymorphisms and the survivin expression of corresponding tumor tissues in order to detect whether the SNPs influence survivin expression or not. Moreover, we have compared the frequency of four survivin promoter polymorphisms in Chinese sporadic esophageal cancer patients and healthy controls in an attempt to identify a possible association between individual genetic variation and susceptibility to esophageal cancer.
CpG methylation is thought to be critical for regulating transcription by the GC rich region around the transcription start site. Survivin has a large CpG island spanning from promoter to exon1 region, which increases the possibility that survivin overexpression in cancers may be the result of the dys-methylation status in neoplastic cells. However, Li and Altieri demonstrated that the CpG island in the survivin promoter was unmethylated in both normal and neoplastic tissues in breast, lung and colon cancers. In contrast, there were other researches reporting that demethylation of CpG sites in the survivin gene exon 1 was involved in the survivin expression in ovarian and oral cancers. These different data indicated that the methylation status of the human survivin promoter might depend on the different CpG sites reserchers detected. We are interested in the methylation status of survivin exon 1 region in esophageal cancer, so whether the CpG island in survivin gene is methylated in normal cells and unmethylated in esophageal cancer were studied in this research.
In summary, our study is to investigate the mechanisms of survivin overexpression in esophageal cancer, the following data showed the contents and results of our study:
1. Esophageal cancer with mutant p53 showed higher survivin gene expression. We measured survivin mRNA expression using RT-PCR in esophageal cancer and adjacent non-cancerous tissues of 100 patients. PCR-single-strand conformation polymorphism (SSCP) analysis was used to detect exons 5–8 mutations of the p53 gene in espohageal cancer tissues. To determine whether the loss of wild type p53 enhanced survivin gene expression in esophageal cancer tissue, the relationship between survivin mRNA expression and p53 gene mutation was analyzed. The ratio of survivin-positive tumors was significantly higher in tumors with mutant p53 than that in tumors with wild type p53 (P=0.020).
2. Polymorphisms of survivin promoter were identified using the PCR-RFLP technique (-31G/C, -141G/C, -241T/C) or primer-introduced restriction analysis-PCR assay (-644T/C, -625G/C). We compared these SNPs’distribution in Chinese Han nationality of Chongqing city with the data in NCBI database about the frequency distribution in other race of people. We found significant differences in allele frequencies of -31G/C, -241T/C and -644T/C polymorphisms between Chinese Han nationality of Chongqing city and the NCBI data of global people. The allele frequencies of -31G/C and -644T/C polymorphisms in Chinese Han nationality of Chongqing city were equal to the NCBI’Asia data, but were different to the European and African data. There was significant difference in allele frequencies of -625G/C polymorphisms between Chinese Han nationality of Chongqing city and the NCBI data of Asia and African people.
3. Polymorphisms of Survivin Promoter Are Associated with Risk of Esophageal Cancer. The frequencies of -644T/C and -31G/C polymorphisms were not significantly different between patients and controls. However, the significant differences in both allele and genotype frequencies between esophageal cancer patients and cancer-free controls were found in -625G/C polymorphism. Compared with the other genotype, the -625CC genotype was associated with significant elevated risk of esophageal cancer (OR=2.120, 95%CI: 1.247-3.603).
4. We examined the combined effect of the survivin promoter polymorphisms, the haplotypes constructed of -644T/C, -625G/C, -31G/C revealed significant associations with esophageal cancer (global P = 0.0034). -644T--625C--31C was a risk haplotype for esophageal cancer (P=0.0001) and -644T?-625G?-31C, a protective haplotype (P = 0.0165).
5. Survivin expression was associated with survivin promoter polymorphisms. The difference between the groups of different survivin expression level was statistically significant to the -625G/C polymorphism (P = 0.024), but not obvious for the -31G/C and -644T/C polymorphisms. The variant C-allele in the -625G/C SNP site was associated with a higher possibility of survivin expression in esophageal cancer patients. Furthermore, the patients with survivin-negative cancer tissues were more likely to exhibit the GG genotype (p=0.033).
6. We investigated the methylation profiles of the survivin exon1 using BSP method in esophageal cancer and adjacent non-cancerous tissues of 4 patients. The cancer tissues we studied were survivin-positive and matched normal tissues were survivin-negative. After BSP, we didn’t find any cytosines in the PCR products’sequences. Therefore, the survivin exon 1 had no methylated CpG site. The survivin-negative non-cancerous tissues and the survivin-positive cancer tissues didn’t show different methylation status in the regions at least in the samples we studied.
Our results revealed an association between p53 mutation and increased survivin expression in esophageal cancer. At the same time, we found the survivin promoter -625CC genotype was more likely to have survivin expression in cancer tissue. These provided substantial mechanism contributing to survivin up-regulation in esophageal cancer. Furthermore, our case-control study suggests a significant association between survivin promoter SNP and esophageal cancer. Moreover, we identified the high consistency of a common risk (-644T?-625C?-31C) and a protective (-644T?-625G?-31C) haplotype in survivin promoter linked with esophageal cancer. To our knowledge, the present study is the first report demonstrating that survivin expression is negatively regulated by p53 gene status in esophageal cancer patients. This is also the first research showing a significant relationship between the survivin promoter -625G/C polymorphism with its mRNA expression and the risk of esophageal cancer. Although the association was statistically significant with the small number of samples, this needs to be confirmed with a larger sample.
引文
1. McCabe ML, Dlamini Z: The molecular mechanisms of oesophageal cancer. Int Immunopharmacol 5:1113-1130,2005.
2. Pickens A, Orringer MB: Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg 76:S1367-1369,2003.
3. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921,1997.
4. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC: Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152:43-49,1998.
5. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, Heine B, Stein H, Hopfner M, Germer CT, Scherubl H: Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 88:115-119,2003.
6. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J et al: Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95:92-95,2001.
7. Ikeguchi M, Yamaguchi K, Kaibara N: Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer. Tumour Biol 24:40-45,2003.
8. Choi N, Baumann M, Flentjie M, Kellokumpu-Lehtinen P, Senan S, Zamboglou N, Kosmidis P: Predictive factors in radiotherapy for non-small cell lung cancer: present status. Lung Cancer 31:43-56,2001.
9. Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R, Shroyer KR: Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol 32:119-125,2001.
10. Nassar A, Lawson D, Cotsonis G, Cohen C: Survivin and Caspase-3 Expression in Breast Cancer: Correlation With Prognostic Parameters, Proliferation, Angiogenesis, and Outcome. Appl Immunohistochem Mol Morphol,2008.
11. Grossman D, McNiff JM, Li F, Altieri DC: Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 113:1076-1081,1999.
12. Ikeguchi M, Kaibara N: survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer 87:883-887,2002.
13. Li F, Altieri DC: Transcriptional analysis of human survivin gene expression. Biochem J 344 Pt 2:305-311,1999.
14. Xu R, Zhang P, Huang J, Ge S, Lu J, Qian G: Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem Biophys Res Commun 356:286-292,2007.
15. Wagner M, Schmelz K, Dorken B, Tamm I: Transcriptional regulation of human survivin by early growth response (Egr)-1 transcription factor. Int J Cancer 122:1278-1287,2008.
16. Gu L, Chiang KY, Zhu N, Findley HW, Zhou M: Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines. Exp Hematol 35:957-966,2007.
17. Jiang Y: Aberrant regulation of survivin by the RB/E2F family of proteins. 279:40511-40520,2004.
18. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR et al: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21:2613-2622,2002.
19. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277:3247-3257,2002.
20. Vegran F, Boidot R, Oudin C, Defrain C, Rebucci M, Lizard-Nacol S: Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 26:290-297,2007.
21. Pizem J, Cor A, Gale N: Survivin expression is a negative prognostic marker in laryngeal squamous cell carcinoma and is associated with p53 accumulation. Histopathology 45:180-186,2004.
22. Nakano J, Huang CL, Liu D, Ueno M, Sumitomo S, Yokomise H: Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer. Int J Oncol 27:1215-1221,2005.
23. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58:5071-5074,1998.
24.关健,陈杰,罗玉凤,曹金伶,赵和,郝君: Survivin在人结直肠腺瘤和腺癌组织中的表达.中国医学科学院学报29:398-402,2007.
25. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6:127-134,2000.
26. Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH, Kang YM, Kam S, Kim IS, Jun JE et al: Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer,2007.
27. Hattori M, Sakamoto H, Satoh K, Yamamoto T: DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett 169:155-164,2001.
28. Tanaka C, Uzawa K, Shibahara T, Yokoe H, Noma H, Tanzawa H: Expression of an inhibitor of apoptosis, survivin, in oral carcinogenesis. J Dent Res 82:607-611,2003.
29. Raj D, Liu T, Samadashwily G, Li F, Grossman D: Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis 29:194-201,2008.
30. Yu J, Ni M, Xu J, Zhang H, Gao B, Gu J, Chen J, Zhang L, Wu M, Zhen S et al: Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2:29,2002.
31. Yu J, Zhang H, Gu J, Lin S, Li J, Lu W, Wang Y, Zhu J: Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 4:65,2004.
32. Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80:1803-1804,1997.
33. Bassam BJ, Caetano-Anolles G, Gresshoff PM: Fast and sensitive silver staining of DNA in polyacrylamide gels. Anal Biochem 196:80-83,1991.
34. Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, Watanabe N: Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91:1204-1209,2000.
35. Xing N, Qian J, Bostwick D, Bergstralh E, Young CY: Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 48:7-15,2001.
36. Azuhata T, Scott D, Takamizawa S, Wen J, Davidoff A, Fukuzawa M, Sandler A: The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J Pediatr Surg 36:1785-1791,2001.
37. Okada E, Murai Y, Matsui K, Isizawa S, Cheng C, Masuda M, Takano Y: Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 163:109-116,2001.
38. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ: Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46:645-650,2000.
39. Hussain SP, Harris CC: Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 58:4023-4037,1998.
40. Knudson AG: Antioncogenes and human cancer. Proc Natl Acad Sci U S A 90:10914-10921,1993.
41. Forrester K, Lupold SE, Ott VL, Chay CH, Band V, Wang XW, Harris CC: Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 10:2103-2111,1995.
42. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B: Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830, 1992.
43. Tabor E: Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J Med Virol 42:357-365,1994.
44. Yamaguchi A, Kurosaka Y, Fushida S, Kanno M, Yonemura Y, Miwa K, Miyazaki I: Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 70:2778-2784,1992.
45. Cesarman E, Inghirami G, Chadburn A, Knowles DM: High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 143:845-856,1993.
46. Kennedy SM, Macgeogh C, Jaffe R, Spurr NK: Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations. Hum Pathol 25:438-442,1994.
47. Xia F, Altieri DC: Mitosis-independent survivin gene expression in vivo and regulationby p53. Cancer Res 66:3392-3395,2006.
48. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B: Definition of a consensus binding site for p53. Nat Genet 1:45-49,1992.
49. Wang L, Wu Q, Qiu P, Mirza A, McGuirk M, Kirschmeier P, Greene JR, Wang Y, Pickett CB, Liu S: Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches. J Biol Chem 276:43604-43610,2001.
50. Punga T, Akusjarvi G: Adenovirus 2 E1B-55K protein relieves p53-mediated transcriptional repression of the survivin and MAP4 promoters. FEBS Lett 552:214-218,2003.
51. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA: Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem 279:40511-40520,2004.
52. Hsieh JK, Yap D, O'Connor DJ, Fogal V, Fallis L, Chan F, Zhong S, Lu X: Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol Cell Biol 22:78-93,2002.
53. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, George DL: Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13:2490-2501,1999.
54. Xu Y, Fang F, Ludewig G, Jones G, Jones D: A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23:527-537,2004.
55. Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH, Kang YM, Kam S, Kim IS, Jun JE et al: Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 60:31-39,2008.
56. Wagner M, Schmelz K, Dorken B, Tamm I: Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leuk Res,2008.
57.蒋知俭:统计分析在医学课题中的应用:人民卫生出版社; 2008.
58. Shi YY, He L: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15:97-98,2005.
59. Stephens M, Scheet P: Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 76:449-462,2005.
60. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989,2001.
61. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M et al: The structure of haplotype blocks in the human genome. Science 296:2225-2229,2002.
62. Ardlie KG, Kruglyak L, Seielstad M: Patterns of linkage disequilibrium in the human genome. Nat Rev Genet 3:299-309,2002.
63. Huang Q, Fu YX, Boerwinkle E: Comparison of strategies for selecting single nucleotide polymorphisms for case/control association studies. Hum Genet 113:253-257,2003.
64. Xu Y, Fang F, Ludewig G, Jones G, Jones D: A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23:419-429,2004.
65. Borbely AA, Murvai M, Szarka K, Konya J, Gergely L, Hernadi Z, Veress G: Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 60:303-306,2007.
66. Demarest SJ, Martinez-Yamout M, Chung J, Chen H, Xu W, Dyson HJ, Evans RM, Wright PE: Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. Nature 415:549-553,2002.
67. Chan HM, La Thangue NB: p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 114:2363-2373,2001.
68. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y: A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382:319-324,1996.
69. Giordano A, Avantaggiati ML: p300 and CBP: partners for life and death. J Cell Physiol 181:218-230,1999.
70. Armas-Pineda C, Arenas-Huertero F, Perezpenia-Diazconti M, Chico-Ponce de Leon F, Sosa-Sainz G, Lezama P, Recillas-Targa F: Expression of PCAF, p300 and Gcn5 and more highly acetylated histone H4 in pediatric tumors. J Exp Clin Cancer Res 26:269-276,2007.
71. Iyer NG, Xian J, Chin SF, Bannister AJ, Daigo Y, Aparicio S, Kouzarides T, Caldas C: p300 is required for orderly G1/S transition in human cancer cells. Oncogene 26:21-29,2007.
72. Pena C, Garcia JM, Garcia V, Silva J, Dominguez G, Rodriguez R, Maximiano C, Garcia de Herreros A, Munoz A, Bonilla F: The expression levels of the transcriptional regulators p300 and CtBP modulate the correlations between SNAIL, ZEB1, E-cadherin and vitamin D receptor in human colon carcinomas. Int J Cancer 119:2098-2104,2006.
73. Rikitake Y, Moran E: DNA-binding properties of the E1A-associated 300-kilodalton protein. Mol Cell Biol 12:2826-2836,1992.
74. Liu X, Wang L, Zhao K, Thompson PR, Hwang Y, Marmorstein R, Cole PA: The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 451:846-850,2008.
75. Bird AP: CpG-rich islands and the function of DNA methylation. Nature 321:209-213,1986.
76. Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229,2001.
77. Esteller M: CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21:5427-5440,2002.
78. Li Q, Ahuja N, Burger PC, Issa JP: Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Oncogene 18:3284-3289,1999.
79. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821-9826,1996.
80. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 89:1827-1831,1992.
81. Yang Y, Takeuchi S, Hofmann WK, Ikezoe T, van Dongen JJ, Szczepanski T, Bartram CR, Yoshino N, Taguchi H, Koeffler HP: Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia. Leuk Res 30:98-102,2006.
82. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G et al: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65:8961-8967,2005.
1. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580-584,1998.
2. Deveraux QL, Reed JC: IAP family proteins--suppressors of apoptosis. Genes Dev 13:239-252,1999.
3. Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP: Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 7:602-608,2000.
4. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921,1997.
5. Chantalat L, Skoufias DA, Kleman JP, Jung B, Dideberg O, Margolis RL: Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol Cell 6:183-189,2000.
6. Kaitna S, Mendoza M, Jantsch-Plunger V, Glotzer M: Incenp and an aurora-like kinase form a complex essential for chromosome segregation and efficient completion of cytokinesis. Curr Biol 10:1172-1181,2000.
7. Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, Kops G, Medema RH: Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. Embo J 22:2934-2947,2003.
8. Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rodel F: Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 55:1341-1347,2003.
9. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS: A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 99:4349-4354,2002.
10. Yamamoto T, Manome Y, Miyamoto A, Tanigawa N: [Development of a novel gene therapy using survivin antisense expressing adenoviral vectors]. Gan To Kagaku Ryoho 30:1805-1808,2003.
11. Yamamoto T, Tanigawa N: The role of survivin as a new target of diagnosis andtreatment in human cancer. Med Electron Microsc 34:207-212,2001.
12. Altieri DC: The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7:542-547,2001.
13. Reed JC: The Survivin saga goes in vivo. J Clin Invest 108:965-969,2001.
14. Altieri DC, Marchisio PC: Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79:1327-1333,1999.
15. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD: Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59:6097-6102,1999.
16. Okada E, Murai Y, Matsui K, Isizawa S, Cheng C, Masuda M, Takano Y: Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 163:109-116,2001.
17. Conway EM, Pollefeyt S, Cornelissen J, DeBaere I, Steiner-Mosonyi M, Ong K, Baens M, Collen D, Schuh AC: Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood 95:1435-1442,2000.
18. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T, Inuzuka M: Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 314:902-907,2004.
19. Caldas H, Honsey LE, Altura RA: Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 4:11,2005.
20. Temme A, Rieger M, Reber F, Lindemann D, Weigle B, Diestelkoetter-Bachert P, Ehninger G, Tatsuka M, Terada Y, Rieber EP: Localization, dynamics, and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell. Mol Biol Cell 14:78-92,2003.
21. Skoufias DA, Mollinari C, Lacroix FB, Margolis RL: Human survivin is a kinetochore-associated passenger protein. J Cell Biol 151:1575-1582,2000.
22. Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL, Choo KH: Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 10:1319-1328,2000.
23. Li F, Altieri DC: Transcriptional analysis of human survivin gene expression.Biochem J 344 Pt 2:305-311,1999.
24. Xu R, Zhang P, Huang J, Ge S, Lu J, Qian G: Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem Biophys Res Commun 356:286-292,2007.
25. Wagner M, Schmelz K, Dorken B, Tamm I: Transcriptional regulation of human survivin by early growth response (Egr)-1 transcription factor. Int J Cancer 122:1278-1287,2008.
26. Endoh A, Asanuma K, Moriai R, Yamada M, Koyanagi Y, Sato T, Yagihasi A, Nakamura M, Kobayashi D, Watanabe N: Expression of survivin mRNA in CD34-positive cells. Clin Chim Acta 306:149-151,2001.
27. Konno R, Yamakawa H, Utsunomiya H, Ito K, Sato S, Yajima A: Expression of survivin and Bcl-2 in the normal human endometrium. Mol Hum Reprod 6:529-534,2000.
28. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46-54,2003.
29. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G et al: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65:8961-8967,2005.
30. Li F, Ling X, Huang H, Brattain L, Apontes P, Wu J, Binderup L, Brattain MG: Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene 24:1385-1395,2005.
31. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR et al: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21:2613-2622,2002.
32. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277:3247-3257,2002.
33. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ: Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatoryprotein, in pancreatic adenocarcinoma. Br J Cancer 86:886-892,2002.
34. Lu CD, Altieri DC, Tanigawa N: Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58:1808-1812,1998.
35. Wang Z, Fukuda S, Pelus LM: Survivin regulates the p53 tumor suppressor gene family. Oncogene 23:8146-8153,2004.
36. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA: Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem 279:40511-40520,2004.
37. Hsieh JK, Yap D, O'Connor DJ, Fogal V, Fallis L, Chan F, Zhong S, Lu X: Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol Cell Biol 22:78-93,2002.
38. Lohr K, Moritz C, Contente A, Dobbelstein M: p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem 278:32507-32516,2003.
39. Li W, Fan J, Bertino JR: Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res 61:2579-2582,2001.
40. Flatt PM, Tang LJ, Scatena CD, Szak ST, Pietenpol JA: p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Mol Cell Biol 20:4210-4223,2000.
41. Song Z, Yao X, Wu M: Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 278:23130-23140,2003.
42. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58:5315-5320,1998.
43. Altieri DC: Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 5:447-452,2003.
44. Honda R, Korner R, Nigg EA: Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 14:3325-3341,2003.
45. O'Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F, Nath AK, Pober JS, Altieri DC: Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 156:393-398,2000.
46. Tran J, Rak J, Sheehan C, Saibil SD, LaCasse E, Korneluk RG, Kerbel RS: Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 264:781-788,1999.
47. Conway EM, Zwerts F, Van Eygen V, DeVriese A, Nagai N, Luo W, Collen D: Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation. Am J Pathol 163:935-946,2003.
48. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N: Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 91:2026-2032,2001.
49. Tu SP, Jiang XH, Lin MC, Cui JT, Yang Y, Lum CT, Zou B, Zhu YB, Jiang SH, Wong WM et al: Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 63:7724-7732,2003.
50. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC: Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 9:2683-2692,2003.
51. Grossman D, McNiff JM, Li F, Altieri DC: Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 113:1076-1081,1999.
52. Allen SM, Florell SR, Hanks AN, Alexander A, Diedrich MJ, Altieri DC, Grossman D: Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Cancer Res 63:567-572,2003.
53. Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra C: Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 9:931-946,2003.
54. Ansell SM, Arendt BK, Grote DM, Jelinek DF, Novak AJ, Wellik LE, Remstein ED, Bennett CF, Fielding A: Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 18:616-623,2004.
55. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC: Mitochondrial survivin inhibitsapoptosis and promotes tumorigenesis. J Clin Invest 114:1117-1127,2004.
56. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T: Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92:271-278,2001.
57. Singh M, Bleile MJ, Shroyer AL, Heinz D, Jarboe EA, Shroyer KR: Analysis of survivin expression in a spectrum of benign to malignant lesions of the breast. Appl Immunohistochem Mol Morphol 12:296-304,2004.
58. Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D et al: Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 9:4914-4925,2003.
59. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, Ashfaq R: Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 100:751-757,2004.
60. Kim HS, Shiraki K, Park SH: Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix. Anticancer Res 22:805-808,2002.
61. Frost M, Jarboe EA, Orlicky D, Gianani R, Thompson LC, Enomoto T, Shroyer KR: Immunohistochemical localization of survivin in benign cervical mucosa, cervical dysplasia, and invasive squamous cell carcinoma. Am J Clin Pathol 117:738-744,2002.
62. Moon WS, Tarnawski AS: Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth? Hum Pathol 34:1119-1126,2003.
63. Ding Y, Prieto VG, Zhang PS, Rosenthal S, Smith KJ, Skelton HG, Diwan AH: Nuclear expression of the antiapoptotic protein survivin in malignant melanoma. Cancer 106:1123-1129,2006.
64. Duffy MJ: Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 38:225-262,2001.
65. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC: Urine detection of survivin and diagnosis of bladder cancer. Jama 285:324-328,2001.
66. Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC, Lerner SP: Urine detection of survivin is a sensitive marker for the noninvasive diagnosis ofbladder cancer. J Urol 171:626-630,2004.
67. Weikert S, Christoph F, Schrader M, Krause H, Miller K, Muller M: Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 116:100-104,2005.
68. Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R, Shroyer KR: Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol 32:119-125,2001.
69. Fukuda S, Foster RG, Porter SB, Pelus LM: The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 100:2463-2471,2002.
70. Pennartz S, Belvindrah R, Tomiuk S, Zimmer C, Hofmann K, Conradt M, Bosio A, Cremer H: Purification of neuronal precursors from the adult mouse brain: comprehensive gene expression analysis provides new insights into the control of cell migration, differentiation, and homeostasis. Mol Cell Neurosci 25:692-706,2004.
71. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF et al: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20:3628-3636,2002.
72. Pantel K, Cote RJ, Fodstad O: Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 91:1113-1124,1999.
73. Gradilone A, Gazzaniga P, Ribuffo D, Scarpa S, Cigna E, Vasaturo F, Bottoni U, Innocenzi D, Calvieri S, Scuderi N et al: Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J Clin Oncol 21:306-312,2003.
74. Duffy MJ: Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 47:624-630,2001.
75. Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB: Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 23:129-137,2004.
76. Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ et al: Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 17:597-604,2006.
77. Li F, Yang J, Ramnath N, Javle MM, Tan D: Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 114:509-512,2005.
78. Mahotka C, Krieg T, Krieg A, Wenzel M, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD: Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 100:30-36,2002.
79. Krieg A, Mahotka C, Krieg T, Grabsch H, Muller W, Takeno S, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD: Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 86:737-743,2002.
80. Ling X, Yang J, Tan D, Ramnath N, Younis T, Bundy BN, Slocum HK, Yang L, Zhou M, Li F: Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer 49:353-361,2005.
81. Taubert H, Kappler M, Bache M, Bartel F, Kohler T, Lautenschlager C, Blumke K, Wurl P, Schmidt H, Meye A et al: Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene 24:5258-5261,2005.
82. Span PN, Tjan-Heijnen VC, Heuvel JJ, de Kok JB, Foekens JA, Sweep FC: Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer? Clin Chem 52:1693-1700,2006.
83. Johnstone RW, Ruefli AA, Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153-164,2002.
84. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F, Daidone MG: Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 59:1406-1412,2002.
85. Span PN, Tjan-Heijnen VC, Manders P, van Tienoven D, Lehr J, Sweep FC: High survivin predicts a poor response to endocrine therapy, but a good response tochemotherapy in advanced breast cancer. Breast Cancer Res Treat 98:223-230,2006.
86. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M: Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 21:315-320,2002.
87. Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, Watanabe N: Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91:1204-1209,2000.
88. Pennati M, Binda M, Colella G, Folini M, Citti L, Villa R, Daidone MG, Zaffaroni N: Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol 120:648-654,2003.
89. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q, Loeffler J: Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 23:7494-7506,2004.
90. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW: Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 93:1541-1552,2001.
91. Zhu N, Gu L, Findley HW, Li F, Zhou M: An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 23:7545-7551,2004.
92. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, Zangemeister-Wittke U: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60:2805-2809,2000.
93. Yonesaka K, Tamura K, Kurata T, Satoh T, Ikeda M, Fukuoka M, Nakagawa K: Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer 118:812-820,2006.
94. Chao JI, Liu HF: The blockage of survivin and securin expression increases the cytochalasin B-induced cell death and growth inhibition in human cancer cells. Mol Pharmacol 69:154-164,2006.
95. Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kuhl-Burmeister R, Adamzik I,Kabelitz D, Dreger P, Schmitz N et al: Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 170:5391-5397,2003.
96. Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM, Shi D, Lee YC, Chang KJ, Hung MC: Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 11:740-747,2004.
97. Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA, Hamilton TC: Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 94:522-528,2002.
98. Fukuda S, Pelus LM: Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 5:1087-1098,2006.
99. Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI: Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 9:6523-6533,2003.
100. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y et al: Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7:457-468,2005.
2. Pickens A, Orringer MB: Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg 76:S1367-1369,2003.
3. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921,1997.
4. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC: Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152:43-49,1998.
5. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, Heine B, Stein H, Hopfner M, Germer CT, Scherubl H: Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 88:115-119,2003.
6. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J et al: Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95:92-95,2001.
7. Ikeguchi M, Yamaguchi K, Kaibara N: Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer. Tumour Biol 24:40-45,2003.
8. Choi N, Baumann M, Flentjie M, Kellokumpu-Lehtinen P, Senan S, Zamboglou N, Kosmidis P: Predictive factors in radiotherapy for non-small cell lung cancer: present status. Lung Cancer 31:43-56,2001.
9. Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R, Shroyer KR: Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol 32:119-125,2001.
10. Nassar A, Lawson D, Cotsonis G, Cohen C: Survivin and Caspase-3 Expression in Breast Cancer: Correlation With Prognostic Parameters, Proliferation, Angiogenesis, and Outcome. Appl Immunohistochem Mol Morphol,2008.
11. Grossman D, McNiff JM, Li F, Altieri DC: Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 113:1076-1081,1999.
12. Ikeguchi M, Kaibara N: survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer 87:883-887,2002.
13. Li F, Altieri DC: Transcriptional analysis of human survivin gene expression. Biochem J 344 Pt 2:305-311,1999.
14. Xu R, Zhang P, Huang J, Ge S, Lu J, Qian G: Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem Biophys Res Commun 356:286-292,2007.
15. Wagner M, Schmelz K, Dorken B, Tamm I: Transcriptional regulation of human survivin by early growth response (Egr)-1 transcription factor. Int J Cancer 122:1278-1287,2008.
16. Gu L, Chiang KY, Zhu N, Findley HW, Zhou M: Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines. Exp Hematol 35:957-966,2007.
17. Jiang Y: Aberrant regulation of survivin by the RB/E2F family of proteins. 279:40511-40520,2004.
18. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR et al: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21:2613-2622,2002.
19. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277:3247-3257,2002.
20. Vegran F, Boidot R, Oudin C, Defrain C, Rebucci M, Lizard-Nacol S: Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 26:290-297,2007.
21. Pizem J, Cor A, Gale N: Survivin expression is a negative prognostic marker in laryngeal squamous cell carcinoma and is associated with p53 accumulation. Histopathology 45:180-186,2004.
22. Nakano J, Huang CL, Liu D, Ueno M, Sumitomo S, Yokomise H: Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer. Int J Oncol 27:1215-1221,2005.
23. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58:5071-5074,1998.
24.关健,陈杰,罗玉凤,曹金伶,赵和,郝君: Survivin在人结直肠腺瘤和腺癌组织中的表达.中国医学科学院学报29:398-402,2007.
25. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6:127-134,2000.
26. Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH, Kang YM, Kam S, Kim IS, Jun JE et al: Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer,2007.
27. Hattori M, Sakamoto H, Satoh K, Yamamoto T: DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett 169:155-164,2001.
28. Tanaka C, Uzawa K, Shibahara T, Yokoe H, Noma H, Tanzawa H: Expression of an inhibitor of apoptosis, survivin, in oral carcinogenesis. J Dent Res 82:607-611,2003.
29. Raj D, Liu T, Samadashwily G, Li F, Grossman D: Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis 29:194-201,2008.
30. Yu J, Ni M, Xu J, Zhang H, Gao B, Gu J, Chen J, Zhang L, Wu M, Zhen S et al: Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2:29,2002.
31. Yu J, Zhang H, Gu J, Lin S, Li J, Lu W, Wang Y, Zhu J: Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 4:65,2004.
32. Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80:1803-1804,1997.
33. Bassam BJ, Caetano-Anolles G, Gresshoff PM: Fast and sensitive silver staining of DNA in polyacrylamide gels. Anal Biochem 196:80-83,1991.
34. Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, Watanabe N: Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91:1204-1209,2000.
35. Xing N, Qian J, Bostwick D, Bergstralh E, Young CY: Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 48:7-15,2001.
36. Azuhata T, Scott D, Takamizawa S, Wen J, Davidoff A, Fukuzawa M, Sandler A: The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J Pediatr Surg 36:1785-1791,2001.
37. Okada E, Murai Y, Matsui K, Isizawa S, Cheng C, Masuda M, Takano Y: Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 163:109-116,2001.
38. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ: Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46:645-650,2000.
39. Hussain SP, Harris CC: Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 58:4023-4037,1998.
40. Knudson AG: Antioncogenes and human cancer. Proc Natl Acad Sci U S A 90:10914-10921,1993.
41. Forrester K, Lupold SE, Ott VL, Chay CH, Band V, Wang XW, Harris CC: Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 10:2103-2111,1995.
42. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B: Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830, 1992.
43. Tabor E: Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J Med Virol 42:357-365,1994.
44. Yamaguchi A, Kurosaka Y, Fushida S, Kanno M, Yonemura Y, Miwa K, Miyazaki I: Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 70:2778-2784,1992.
45. Cesarman E, Inghirami G, Chadburn A, Knowles DM: High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 143:845-856,1993.
46. Kennedy SM, Macgeogh C, Jaffe R, Spurr NK: Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations. Hum Pathol 25:438-442,1994.
47. Xia F, Altieri DC: Mitosis-independent survivin gene expression in vivo and regulationby p53. Cancer Res 66:3392-3395,2006.
48. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B: Definition of a consensus binding site for p53. Nat Genet 1:45-49,1992.
49. Wang L, Wu Q, Qiu P, Mirza A, McGuirk M, Kirschmeier P, Greene JR, Wang Y, Pickett CB, Liu S: Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches. J Biol Chem 276:43604-43610,2001.
50. Punga T, Akusjarvi G: Adenovirus 2 E1B-55K protein relieves p53-mediated transcriptional repression of the survivin and MAP4 promoters. FEBS Lett 552:214-218,2003.
51. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA: Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem 279:40511-40520,2004.
52. Hsieh JK, Yap D, O'Connor DJ, Fogal V, Fallis L, Chan F, Zhong S, Lu X: Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol Cell Biol 22:78-93,2002.
53. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, George DL: Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13:2490-2501,1999.
54. Xu Y, Fang F, Ludewig G, Jones G, Jones D: A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23:527-537,2004.
55. Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH, Kang YM, Kam S, Kim IS, Jun JE et al: Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 60:31-39,2008.
56. Wagner M, Schmelz K, Dorken B, Tamm I: Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leuk Res,2008.
57.蒋知俭:统计分析在医学课题中的应用:人民卫生出版社; 2008.
58. Shi YY, He L: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15:97-98,2005.
59. Stephens M, Scheet P: Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 76:449-462,2005.
60. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989,2001.
61. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M et al: The structure of haplotype blocks in the human genome. Science 296:2225-2229,2002.
62. Ardlie KG, Kruglyak L, Seielstad M: Patterns of linkage disequilibrium in the human genome. Nat Rev Genet 3:299-309,2002.
63. Huang Q, Fu YX, Boerwinkle E: Comparison of strategies for selecting single nucleotide polymorphisms for case/control association studies. Hum Genet 113:253-257,2003.
64. Xu Y, Fang F, Ludewig G, Jones G, Jones D: A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23:419-429,2004.
65. Borbely AA, Murvai M, Szarka K, Konya J, Gergely L, Hernadi Z, Veress G: Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 60:303-306,2007.
66. Demarest SJ, Martinez-Yamout M, Chung J, Chen H, Xu W, Dyson HJ, Evans RM, Wright PE: Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. Nature 415:549-553,2002.
67. Chan HM, La Thangue NB: p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 114:2363-2373,2001.
68. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y: A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382:319-324,1996.
69. Giordano A, Avantaggiati ML: p300 and CBP: partners for life and death. J Cell Physiol 181:218-230,1999.
70. Armas-Pineda C, Arenas-Huertero F, Perezpenia-Diazconti M, Chico-Ponce de Leon F, Sosa-Sainz G, Lezama P, Recillas-Targa F: Expression of PCAF, p300 and Gcn5 and more highly acetylated histone H4 in pediatric tumors. J Exp Clin Cancer Res 26:269-276,2007.
71. Iyer NG, Xian J, Chin SF, Bannister AJ, Daigo Y, Aparicio S, Kouzarides T, Caldas C: p300 is required for orderly G1/S transition in human cancer cells. Oncogene 26:21-29,2007.
72. Pena C, Garcia JM, Garcia V, Silva J, Dominguez G, Rodriguez R, Maximiano C, Garcia de Herreros A, Munoz A, Bonilla F: The expression levels of the transcriptional regulators p300 and CtBP modulate the correlations between SNAIL, ZEB1, E-cadherin and vitamin D receptor in human colon carcinomas. Int J Cancer 119:2098-2104,2006.
73. Rikitake Y, Moran E: DNA-binding properties of the E1A-associated 300-kilodalton protein. Mol Cell Biol 12:2826-2836,1992.
74. Liu X, Wang L, Zhao K, Thompson PR, Hwang Y, Marmorstein R, Cole PA: The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 451:846-850,2008.
75. Bird AP: CpG-rich islands and the function of DNA methylation. Nature 321:209-213,1986.
76. Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229,2001.
77. Esteller M: CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21:5427-5440,2002.
78. Li Q, Ahuja N, Burger PC, Issa JP: Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Oncogene 18:3284-3289,1999.
79. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821-9826,1996.
80. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 89:1827-1831,1992.
81. Yang Y, Takeuchi S, Hofmann WK, Ikezoe T, van Dongen JJ, Szczepanski T, Bartram CR, Yoshino N, Taguchi H, Koeffler HP: Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia. Leuk Res 30:98-102,2006.
82. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G et al: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65:8961-8967,2005.
1. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580-584,1998.
2. Deveraux QL, Reed JC: IAP family proteins--suppressors of apoptosis. Genes Dev 13:239-252,1999.
3. Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP: Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 7:602-608,2000.
4. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921,1997.
5. Chantalat L, Skoufias DA, Kleman JP, Jung B, Dideberg O, Margolis RL: Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol Cell 6:183-189,2000.
6. Kaitna S, Mendoza M, Jantsch-Plunger V, Glotzer M: Incenp and an aurora-like kinase form a complex essential for chromosome segregation and efficient completion of cytokinesis. Curr Biol 10:1172-1181,2000.
7. Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, Kops G, Medema RH: Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. Embo J 22:2934-2947,2003.
8. Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rodel F: Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 55:1341-1347,2003.
9. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS: A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 99:4349-4354,2002.
10. Yamamoto T, Manome Y, Miyamoto A, Tanigawa N: [Development of a novel gene therapy using survivin antisense expressing adenoviral vectors]. Gan To Kagaku Ryoho 30:1805-1808,2003.
11. Yamamoto T, Tanigawa N: The role of survivin as a new target of diagnosis andtreatment in human cancer. Med Electron Microsc 34:207-212,2001.
12. Altieri DC: The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7:542-547,2001.
13. Reed JC: The Survivin saga goes in vivo. J Clin Invest 108:965-969,2001.
14. Altieri DC, Marchisio PC: Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79:1327-1333,1999.
15. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD: Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59:6097-6102,1999.
16. Okada E, Murai Y, Matsui K, Isizawa S, Cheng C, Masuda M, Takano Y: Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 163:109-116,2001.
17. Conway EM, Pollefeyt S, Cornelissen J, DeBaere I, Steiner-Mosonyi M, Ong K, Baens M, Collen D, Schuh AC: Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood 95:1435-1442,2000.
18. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T, Inuzuka M: Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 314:902-907,2004.
19. Caldas H, Honsey LE, Altura RA: Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 4:11,2005.
20. Temme A, Rieger M, Reber F, Lindemann D, Weigle B, Diestelkoetter-Bachert P, Ehninger G, Tatsuka M, Terada Y, Rieber EP: Localization, dynamics, and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell. Mol Biol Cell 14:78-92,2003.
21. Skoufias DA, Mollinari C, Lacroix FB, Margolis RL: Human survivin is a kinetochore-associated passenger protein. J Cell Biol 151:1575-1582,2000.
22. Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL, Choo KH: Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 10:1319-1328,2000.
23. Li F, Altieri DC: Transcriptional analysis of human survivin gene expression.Biochem J 344 Pt 2:305-311,1999.
24. Xu R, Zhang P, Huang J, Ge S, Lu J, Qian G: Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem Biophys Res Commun 356:286-292,2007.
25. Wagner M, Schmelz K, Dorken B, Tamm I: Transcriptional regulation of human survivin by early growth response (Egr)-1 transcription factor. Int J Cancer 122:1278-1287,2008.
26. Endoh A, Asanuma K, Moriai R, Yamada M, Koyanagi Y, Sato T, Yagihasi A, Nakamura M, Kobayashi D, Watanabe N: Expression of survivin mRNA in CD34-positive cells. Clin Chim Acta 306:149-151,2001.
27. Konno R, Yamakawa H, Utsunomiya H, Ito K, Sato S, Yajima A: Expression of survivin and Bcl-2 in the normal human endometrium. Mol Hum Reprod 6:529-534,2000.
28. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46-54,2003.
29. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G et al: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65:8961-8967,2005.
30. Li F, Ling X, Huang H, Brattain L, Apontes P, Wu J, Binderup L, Brattain MG: Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene 24:1385-1395,2005.
31. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR et al: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21:2613-2622,2002.
32. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277:3247-3257,2002.
33. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ: Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatoryprotein, in pancreatic adenocarcinoma. Br J Cancer 86:886-892,2002.
34. Lu CD, Altieri DC, Tanigawa N: Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58:1808-1812,1998.
35. Wang Z, Fukuda S, Pelus LM: Survivin regulates the p53 tumor suppressor gene family. Oncogene 23:8146-8153,2004.
36. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA: Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem 279:40511-40520,2004.
37. Hsieh JK, Yap D, O'Connor DJ, Fogal V, Fallis L, Chan F, Zhong S, Lu X: Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol Cell Biol 22:78-93,2002.
38. Lohr K, Moritz C, Contente A, Dobbelstein M: p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem 278:32507-32516,2003.
39. Li W, Fan J, Bertino JR: Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res 61:2579-2582,2001.
40. Flatt PM, Tang LJ, Scatena CD, Szak ST, Pietenpol JA: p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Mol Cell Biol 20:4210-4223,2000.
41. Song Z, Yao X, Wu M: Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 278:23130-23140,2003.
42. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58:5315-5320,1998.
43. Altieri DC: Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 5:447-452,2003.
44. Honda R, Korner R, Nigg EA: Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 14:3325-3341,2003.
45. O'Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F, Nath AK, Pober JS, Altieri DC: Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 156:393-398,2000.
46. Tran J, Rak J, Sheehan C, Saibil SD, LaCasse E, Korneluk RG, Kerbel RS: Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 264:781-788,1999.
47. Conway EM, Zwerts F, Van Eygen V, DeVriese A, Nagai N, Luo W, Collen D: Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation. Am J Pathol 163:935-946,2003.
48. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N: Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 91:2026-2032,2001.
49. Tu SP, Jiang XH, Lin MC, Cui JT, Yang Y, Lum CT, Zou B, Zhu YB, Jiang SH, Wong WM et al: Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 63:7724-7732,2003.
50. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC: Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 9:2683-2692,2003.
51. Grossman D, McNiff JM, Li F, Altieri DC: Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 113:1076-1081,1999.
52. Allen SM, Florell SR, Hanks AN, Alexander A, Diedrich MJ, Altieri DC, Grossman D: Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Cancer Res 63:567-572,2003.
53. Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra C: Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 9:931-946,2003.
54. Ansell SM, Arendt BK, Grote DM, Jelinek DF, Novak AJ, Wellik LE, Remstein ED, Bennett CF, Fielding A: Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 18:616-623,2004.
55. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC: Mitochondrial survivin inhibitsapoptosis and promotes tumorigenesis. J Clin Invest 114:1117-1127,2004.
56. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T: Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92:271-278,2001.
57. Singh M, Bleile MJ, Shroyer AL, Heinz D, Jarboe EA, Shroyer KR: Analysis of survivin expression in a spectrum of benign to malignant lesions of the breast. Appl Immunohistochem Mol Morphol 12:296-304,2004.
58. Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D et al: Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 9:4914-4925,2003.
59. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, Ashfaq R: Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 100:751-757,2004.
60. Kim HS, Shiraki K, Park SH: Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix. Anticancer Res 22:805-808,2002.
61. Frost M, Jarboe EA, Orlicky D, Gianani R, Thompson LC, Enomoto T, Shroyer KR: Immunohistochemical localization of survivin in benign cervical mucosa, cervical dysplasia, and invasive squamous cell carcinoma. Am J Clin Pathol 117:738-744,2002.
62. Moon WS, Tarnawski AS: Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth? Hum Pathol 34:1119-1126,2003.
63. Ding Y, Prieto VG, Zhang PS, Rosenthal S, Smith KJ, Skelton HG, Diwan AH: Nuclear expression of the antiapoptotic protein survivin in malignant melanoma. Cancer 106:1123-1129,2006.
64. Duffy MJ: Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 38:225-262,2001.
65. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC: Urine detection of survivin and diagnosis of bladder cancer. Jama 285:324-328,2001.
66. Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC, Lerner SP: Urine detection of survivin is a sensitive marker for the noninvasive diagnosis ofbladder cancer. J Urol 171:626-630,2004.
67. Weikert S, Christoph F, Schrader M, Krause H, Miller K, Muller M: Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 116:100-104,2005.
68. Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R, Shroyer KR: Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol 32:119-125,2001.
69. Fukuda S, Foster RG, Porter SB, Pelus LM: The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 100:2463-2471,2002.
70. Pennartz S, Belvindrah R, Tomiuk S, Zimmer C, Hofmann K, Conradt M, Bosio A, Cremer H: Purification of neuronal precursors from the adult mouse brain: comprehensive gene expression analysis provides new insights into the control of cell migration, differentiation, and homeostasis. Mol Cell Neurosci 25:692-706,2004.
71. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF et al: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20:3628-3636,2002.
72. Pantel K, Cote RJ, Fodstad O: Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 91:1113-1124,1999.
73. Gradilone A, Gazzaniga P, Ribuffo D, Scarpa S, Cigna E, Vasaturo F, Bottoni U, Innocenzi D, Calvieri S, Scuderi N et al: Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J Clin Oncol 21:306-312,2003.
74. Duffy MJ: Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 47:624-630,2001.
75. Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB: Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 23:129-137,2004.
76. Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ et al: Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 17:597-604,2006.
77. Li F, Yang J, Ramnath N, Javle MM, Tan D: Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 114:509-512,2005.
78. Mahotka C, Krieg T, Krieg A, Wenzel M, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD: Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 100:30-36,2002.
79. Krieg A, Mahotka C, Krieg T, Grabsch H, Muller W, Takeno S, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD: Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 86:737-743,2002.
80. Ling X, Yang J, Tan D, Ramnath N, Younis T, Bundy BN, Slocum HK, Yang L, Zhou M, Li F: Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer 49:353-361,2005.
81. Taubert H, Kappler M, Bache M, Bartel F, Kohler T, Lautenschlager C, Blumke K, Wurl P, Schmidt H, Meye A et al: Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene 24:5258-5261,2005.
82. Span PN, Tjan-Heijnen VC, Heuvel JJ, de Kok JB, Foekens JA, Sweep FC: Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer? Clin Chem 52:1693-1700,2006.
83. Johnstone RW, Ruefli AA, Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153-164,2002.
84. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F, Daidone MG: Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 59:1406-1412,2002.
85. Span PN, Tjan-Heijnen VC, Manders P, van Tienoven D, Lehr J, Sweep FC: High survivin predicts a poor response to endocrine therapy, but a good response tochemotherapy in advanced breast cancer. Breast Cancer Res Treat 98:223-230,2006.
86. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M: Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 21:315-320,2002.
87. Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, Watanabe N: Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91:1204-1209,2000.
88. Pennati M, Binda M, Colella G, Folini M, Citti L, Villa R, Daidone MG, Zaffaroni N: Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol 120:648-654,2003.
89. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q, Loeffler J: Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 23:7494-7506,2004.
90. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW: Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 93:1541-1552,2001.
91. Zhu N, Gu L, Findley HW, Li F, Zhou M: An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 23:7545-7551,2004.
92. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, Zangemeister-Wittke U: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60:2805-2809,2000.
93. Yonesaka K, Tamura K, Kurata T, Satoh T, Ikeda M, Fukuoka M, Nakagawa K: Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer 118:812-820,2006.
94. Chao JI, Liu HF: The blockage of survivin and securin expression increases the cytochalasin B-induced cell death and growth inhibition in human cancer cells. Mol Pharmacol 69:154-164,2006.
95. Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kuhl-Burmeister R, Adamzik I,Kabelitz D, Dreger P, Schmitz N et al: Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 170:5391-5397,2003.
96. Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM, Shi D, Lee YC, Chang KJ, Hung MC: Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 11:740-747,2004.
97. Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA, Hamilton TC: Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 94:522-528,2002.
98. Fukuda S, Pelus LM: Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 5:1087-1098,2006.
99. Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI: Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 9:6523-6533,2003.
100. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y et al: Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7:457-468,2005.